Clinical trials
Peripheral Arterial Disease trials in Italy with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Recruiting | 5 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Medtronic Endovascular | 2 |
| University Hospital of Ferrara | 2 |
| W.L.Gore & Associates | 2 |
| Azienda Ospedaliero-Universitaria di Parma | 1 |
| CID - Carbostent & Implantable Devices | 1 |
| Carelon Research | 1 |
| Cook Group Incorporated | 1 |
| Cordis US Corp. | 1 |
| Dr. Sabrina Overhagen | 1 |
| Endologix | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peripheral Arterial Disease | 22 |
| Chronic Limb-Threatening Ischemia | 3 |
| Diabetes Mellitus | 2 |
| Intermittent Claudication | 2 |
| Peripheral Vascular Diseases | 2 |
| Vascular Diseases | 2 |
| Arteriosclerosis Obliterans | 1 |
| Atherosclerosis | 1 |
| Atrial Fibrillation | 1 |
| Cardiovascular Diseases | 1 |
Trials
Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.